Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-08-15

Clinical Trial Update: Study of E7389 for Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of E7389 (eribulin) for advanced or metastatic breast cancer has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • E7389 (eribulin)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-08-15